Advertisement

Future Directions

  • Ian Fentiman
Chapter

Abstract

A rare disease can be a source of worry for both the patient and the doctor. There is one approach which will improve the treatment of male breast cancer and convince the patient that he is being managed optimally and that is to set up collaborative clinical and research networks based around a few hubs. At present, prevention is not a feasible option but health education has an important role in dispelling ignorance and encouraging early presentation of those with potential symptoms or signs of male breast cancer. Structured investigation should enable the majority to be reassured while the few with cancer can be promptly diagnosed and, when possible, specimens obtained not only for routine pathology but also for research tissue banks. There needs to be a greater emphasis on neoadjuvant treatment, mostly endocrine in nature to shrink primary tumours and enable more men to have less mutilating surgery. In the past many attempts were made to establish the similarities between male and female breast cancer. Sophisticated molecular analyses are now identifying multiple striking differences and the exploitation of these will in time lead to better prognostic models and new tailored therapies for male breast cancer.

Keywords

Breast Cancer Male Breast Cancer Danish Breast Cancer Cooperative Group Nipple Involvement Breast Care Nurse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103:1461–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008;109:573–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367:1792–802.CrossRefPubMedGoogle Scholar
  4. 4.
    Jensen MB, Ejlertsen B, Mouridsen HT, Christiansen P, Danish Breast Cancer Cooperative Group. Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol. 2016;55 SupplGoogle Scholar
  5. 5.
    Stronegger WJ, Freidl W, Rásky E. Health behaviour and risk behaviour: socioeconomic differences in an Austrian rural county. Soc Sci Med. 1997;44:423–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Hassan I, Mabogunje O. Cancer of the male breast in Zaria, Nigeria. East Afr Med J. 1995;72:457–8.PubMedGoogle Scholar
  7. 7.
    Ahmed A, Ukwenya Y, Abdullahi A, Muhammad I. Management and outcomes of male breast cancer in Zaria, Nigeria. Int J Breast Cancer. 2012;2012:845143.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hallowell N, Arden-Jones A, Eeles R, Foster C, Lucassen A, et al. Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family. Sociol Health Illn. 2006;28:969–88.CrossRefPubMedGoogle Scholar
  9. 9.
    Bicchierai G, Nori J, Livi L, De Benedetto D, Vanzi E. Core needle biopsy for the assessment of unilateral male breast lesions. Eur J Surg Oncol. 2016. S0748-7983(16)30847-2. doi:  10.1016/j.ejso.2016.07.144. [Epub ahead of print].
  10. 10.
    Cocco P, Figgs L, Dosemeci M, Hayes R, Linet MS, Hsing AW. Case–control study of occupational exposures and male breast cancer. Occup Environ Med. 1998;55:599–604.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg. 1995;82:341.CrossRefPubMedGoogle Scholar
  12. 12.
    Pattison ST, McLaren BR. Triple negative breast cancer in a male-to-female transsexual. Intern Med J. 2013;43:203–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women’s Health Initiative randomized clinical trials. JAMA Oncol. 2015;1:296–305.CrossRefPubMedGoogle Scholar
  14. 14.
    Brinton LA, Cook MB, McCormack V, Johnson KC, Olsson H, et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst. 2014;106(3):djt465. doi: 10.1093/jnci/djt465.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, et al. Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87:1234–45.CrossRefPubMedGoogle Scholar
  16. 16.
    Orr N, Cooke R, Jones M, Fletcher O, Dudbridge F, et al. Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in men. PLoS Genet. 2011;7(9):e1002290. doi: 10.1371/journal.pgen.1002290.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Andres SA, Smolenkova IA, Wittliff JL. Gender-associated expression of tumor markers and a small gene set in breast carcinoma. Breast. 2014;23:226–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Gonzalez RS, Wang J, Kraus T, Sullivan H, Adams AL, Cohen C. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum Pathol. 2013;44:1065–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Schildhaus HU, Schroeder L, Merkelbach-Bruse S, Binot E, et al. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes. Breast. 2013;22:1066–71.CrossRefPubMedGoogle Scholar
  20. 20.
    Kanthan R, Fried I, Rueckl T, Senger JL, Kanthan SC. Expression of cell cycle proteins in male breast carcinoma. World J Surg Oncol. 2010;8:10–20.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Millican-Slater RA, Sayers CD, Hanby AM, Hughes TA. Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer. Br J Cancer. 2016; doi: 10.1038/bjc.2016.178. [Epub ahead of print].PubMedGoogle Scholar
  22. 22.
    Doyen J, Italiano A, Largillier R, Ferrero J-M, Fontana X, Thyss A. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol. 2010;21:1243–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Yu E, Suzuki H, Younus J, Elfiki T, Stitt L, Yau G, et al. The impact of post-mastectomy radiation therapy on male breast cancer patients–a case series. Int J Radiat Oncol Biol Phys. 2012;82:696–700.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Ian Fentiman
    • 1
  1. 1.Research OncologyGuy’s HospitalLondonUnited Kingdom

Personalised recommendations